论文部分内容阅读
系统性红斑狼疮(SLE)是一种病因不明的慢性自身免疫性疾病,可导致多系统的损害。本病目前治疗手段有限,多数药物作用机制为针对患者的免疫应答失衡。合成肽作为一种新型药物,靶向作用于狼疮发病机制相关细胞表面的特定抗原,因此具有针对性强、副作用少的优点。合成肽具有诱导免疫耐受的作用,并且可改善小鼠模型中该疾病的临床表现。本文对合成肽治疗系统性红斑狼疮的临床前研究和作用机制作一综述。
Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease of unknown etiology that causes multiple systemic damage. The current treatment of the disease is limited, the majority of drug mechanism of action for the immune response imbalance in patients. Synthetic peptides, as a new class of drugs, target specific antigens on the surface of cells associated with the pathogenesis of lupus and are therefore highly targeted and have fewer side effects. Synthetic peptides have the effect of inducing immune tolerance and can improve the clinical manifestations of the disease in a mouse model. This review summarizes the preclinical studies and the mechanisms of action of synthetic peptides in the treatment of systemic lupus erythematosus.